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[57] ABSTRACT 
A compound of the formula 
wherein R and R‘ together represent a primary or a second 
ary aliphatic amine. Also described are elastase enzyme 
inhibitory compositions including a carrier and an elastase 
enzyme inhibiting amount of the compounds of the inven 
tion. A method of selectively inhibiting the enzyme elastase 
in an animal or a human in need of such treatment includes 
administering to the animal or human an enzyme elastase 
inhibiting amount of one of the compounds of the invention 
or a composition thereof. 
19 Claims, 5 Drawing Sheets 
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LOW MOLECULAR WEIGHT 
THIOCARBAMATES AS INHIBITORS OF 
ELASTASE, USES AND METHOD OF 
SYNTHESIS 
TECHNICAL FIELD 
This invention relates to potent low molecular weight 
thiocarbamate inhibitors of the enzyme elastase and to their 
utilization for inhibiting the activity of the enzyme in 
animals and humans. The invention also relates to a treat 
ment of chronic tissue destruction in animals or humans, 
associated with a condition selected from the group consist~ 
ing of in?arrunation, arthritis, emphysema, bronchitis, acute 
respiratory distress syndrome (ARDS), cystic ?brosis, and 
other conditions requiring elastase inhibition to reduce 
symptoms. 
BACKGROUND 
Proteinases from polymorphonuclear leukocytes and 
macrophages, especially elastases, for example human leu 
kocyte elastase and cathepsin G, appear to be responsible for 
the chronic tissue destruction associated with in?ammation, 
arthritis and emphysema. During infection or in?ammation, 
the normal lung is protected from proteolytic digestion by 
the protease inhibitor, otl -antitrypsin. The protective mecha 
nism appears to be nonoperative in individuals with an 
otl-antitrypsin de?ciency due to genetic or other causes. 
Synthetic elastase inhibitors capable of replacing otl-antit 
rypsin may therefore be useful in the treatment of pulmonary 
emphysema and related diseases. 
Several types of elastase inhibitors have been reported in 
the literature. These include peptide chloromethyl ketones as 
described by P. M. Tuhy and J. C. Powers, “Inhibition of 
Human Leukocyte Elastase by Peptide Chloromethyl 
Ketones”, FEBS Letters, 50, 359—61 (1975); J. C. Powers, 
B. F. Gupton, A. D. Harley, N. Nishino and R. J. Whitley, 
“Speci?city of Porcine Pancreatic Elastase, Human Leuko 
cyte Elastase and Cathepsin G. Inhibition with Peptide 
Chloromethyl Ketones”, Biochem. Biophys. Acta. 485, 
156—66 (1977); azapeptides, C. P. Dorn, M. Zirrunerrnan, S. 
S. Yang, E. C. Yurewicz, B. M. Ashe, R. Frankshun and H. 
Jones, “Proteinase Inhibitors. l. Inhibitors of Elastase”, J. 
med. Chem, 20, 1464-68 (1977); J. C. Powers and B. F. 
Gupton, “Reaction of Serine Proteases with Aza-amino Acid 
and Aza‘peptide Derivatives”, Meth. Enzymol., 46,208-16 
(1977); sulfonyl ?uorides, T. Yoshimura, L. N. Barker and J. 
C. Powers, “Speci?city and. Reactivity of Human Leuko 
cyte Elastase, Porcine Pancreatic Elastase, Human Granu 
locyte Cathepsin G, and Bovine Pancreatic Elastase, Human 
Granulocyte Cathepsin G, and Bovine pancreatic Chym0t~ 
rypsin with Arylsulfonyl Fluorides. Discovery of a new 
series of potent and speci?c irreversible Elastase Inhibitors”, 
J. Biol. Chem. 257, 5077-—84 (1982); heterocyclic acylating 
agents, M. Zimmerman, H. Morrnan, D. Mulvey, H. Jones, 
R. Frankshum and B. M. Ashe, “Inhibition of Elastase and 
Other Serine Proteases by Heterocyclic Acylating Agents”, 
J. Biol. Chem. 25, 9848-51 (1980); B. M. Ashe, R. L. Clark, 
H. Jones and M. Zimmerman, “Selective Inhibition of 
Human Leukocyte Elastase and Bovine a1 -Chymotrypsin by 
Novel Heterocycles”, J. Biol. Chem. 256: 11603—6(1981); 
irnidazole N -carboxamides, W. C. Groutas, R. C. Badger, T. 
D. Ocain, D. Felder, J. Frankson and M. Theodorakis, 
Biochem. Biophys. Res. Commun, 95, 1890 (1980); and 
p-nitrophenyl-N alkyl carbamates, R. E. Sco?eld, R. P. 
Werner and F. Wold, “p-Nitrophenyl Carbamates as Active 
20 
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2 
Site-Speci?c Reagents for Serine Proteases”, Biochemistry, 
16, 2492 (1977). 
Some peptide chloromethyl ketones have been shownto 
be effective in preventing elastase induced emphysema in 
animal models, A. Jaoff and R. Dearing, “Prevention of 
Elastase Induced Experimental Emphysema by Oral Admin 
istration of Synthetic Elastase Inhibitor”, Am. J. Respir. Dis. 
121, 1025-3 (1980). However, there is considerable question 
whether such reactive agents can be used for treating 
emphysema in humans. This is not surprising since the 
alkylating moieties in these inhibitors might render them 
toxic when used on a continuous basis. 
U.S. Pat. No. 4,643,991, Tsuji K. et al, B.B.R.C. 
122(2):571 (1984) and Digenis, G. A. et al, J. Med. Chem. 
2921468 (1986) describe peptide elastase inhibitors which 
are speci?c and active-site directed. 
Human Leucocyte Elastase (HLE) is a serine-dependent 
protease, which degrades elastin found in all elastic tissues. 
A growing body of experimental evidence indicates that this 
enzyme may be involved in tissue destruction associated 
with such disease states as arthritis, bronchitis, in?amma 
tion, acute respiratory distress syndrome (ARDS), cystic 
?brosis, and pulmonary emphysema. In a healthy tissue a 
balance exists between elastase and the natural occurring 
antiprotease al-antitrypsin. Emphysema and other related 
diseases has been postulated to result from an imbalance 
between proteases such as HLE and their naturally occurring 
inhibitors (antiproteases) in the lung and other related tis 
sues. Severe genetic de?ciency in al-antitrypsin is fre 
quently associated with development of pulmonary emphy 
sema. 
During the last 10 years potent oligopeptidyl carbamate 
esters like (PCl) (see formula 2) (U.S. Pat. No. 5,162,307) 
and (PCS) (see formula 2) (U.S. Pat. No. 4,643,991) have 
been shown to speci?cally inhibit HLE without inhibiting 
other similar enzymes in the body. The disadvantages of the 
oligopeptide inhibitors are ?rst their multistep painstaking 
synthesis and puri?cation which may render them expensive 
and di?icult to manufacture, and second their questionable 
bioavailability especially oral due to their instability (chemi 
cal or enzymatic) in the G1. tract. 
To be suitable for human use, an enzyme inhibitor has to 
show a high degree of selectivity and must have minimal 
toxic side effects. As a result, most drugs are molecules that 
reversibly bind to speci?c enzymes or receptor sites. 
Examples are the carbamate esters physostigmine and neo 
stigmine which have been clinically used as inhibitors of 
acetyl choline esterases (A. G. Gilman, L. S. Goodman, and 
A. Gilman, “The pharmacological Basis of Therapeutics”, p. 
101, MacMillan Publishing Co. (1980)). 
There is a need in the art for simple carbamate esters 
which are elastase inhibitors which have increased stability, 
activity and oral bioavailability. 
The present invention overcomes the de?ciencies of the 
prior art by providing for the design and synthesis of 
inhibitors of elastase which are simple carbamate esters with 
increased stability and oral bioavailability. The present 
invention elucidates the mechanism by which these carbam 
ate esters inhibit elastase in vitro. The bioavailability and 
pharmacologic activity of the compounds of the invention, 
the most potent inhibitors of elastase, is shown in experi 
mental animals in vivo. The compounds of the invention, 
unexpectedly and advantageously are more potent than 
known elastase inhibitors PC-l and PC-S. In addition the 
compounds of the present invention unexpectedly and 
advantageously have increased absorption and bioavailabil 
ity over the compounds PC-l and PC-5. 
5,539,123 
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DISCLOSURE OF THE INVENTION 
The present invention is directed to a compound com 
prising a thiocarbamate including a primary or a secondary 
aliphatic amine~and a l-phenyl-lH-tetrazole-S-thiol. The 
present invention provides for a compound of the formula: 
15 
wherein R and R‘ together comprise a primary or a second 
ary aliphatic amine. Preferably the compound is a primary 
aliphatic amine, wherein R selected from the group consist 
ing of CH3CH2CH2CH2——; CH2=CH—CH2——; 2O 
CH3—|CH—; 
CH3 
and a phenyl group and R' is H. 25 
Alternatively, the compound of the invention is a second 
ary aliphatic amine, wherein R’ is selected from the Group 
consisting of CH3CH2CH2CH2——; 
CH3—CH-; 
| 30 
CH3 
and R is selected from CH3—CH2 and 
CH3—CH—. 
| 35 
CH3 
The compound preferably is a compound which includes 
a primary or a secondary aliphatic amine and is selected 
from the group consisting of thiocarbamates N-butyl, l~phe- 40 
nyl-lH—tetrazole-5-thiocarbamate; N-allyl, l-phenyl-lH-tet 
razole-S-thiocarbamate; N-isopropyl, l-phenyl-lH-tetra— 
zole-S-thiocarbamate; and N-phenyl, l-phenyl-lH 
tetrazole-S-thiocarbamate, N-Ethyl-N-n-butyl, l-phenyl 
lH-tetrazole-S-thiocarbamate, and N,N~diisopropyl, 45 
l-phenyl- l H-tetrazole-S-thiocarbamate. 
The compounds of the invention are useful in a method 
for the inhibition of elastase enzyme, particularly human 
leukocyte elastase, N-butyl, l-phenyl-lH-tetrazole-S-thio 
carbamate; N-allyl, l-phenyl-lH-tetrazole-S-thiocarbamate; 50 
N-isopropyl, l-phenyl-1H-tetrazole-S-thiocarbamate; and 
N-phenyl, l-phenyl- l H-tetrazole-5~thiocarbamate. 
An object of the invention is to provide a method for the 
inhibition of elastase enzyme wherein said patient has 
chronic tissue destruction associated with a condition 55 
selected from the group consisting of in?ammation, arthritis, 
emphysema, bronchitis, acute respiratory distress syndrome 
(ARDS), and cystic ?brosis and other conditions requiring 
elastase inhibition to reduce symptoms. 
Still another object of the invention is to provide for 60 
pharmaceutical compositions comprising the thiocarbamate 
compounds of the invention, including a primary or a 
secondary aliphatic amine and a l-phenyl-lH-tetrazole-S 
thiol, and a pharmaceutically acceptable carrier. 
Preferably, the pharmaceutical composition includes a 65 
compound with a primary aliphatic amine which is selected 
from the group consisting of thiocarbamates N-butyl, l-phe 
4 
nyl- l H-tetrazole-5~thiocarbamate; N-allyl, l-phenyl- lH-tet 
razole-S-thiocarbamate; N-isopropyl, l-phenyl-lH-tetra 
zole-5-thiocarbamate; and N-phenyl, l-phenyl~lH 
tetrazole-S-thiocarbamate. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. 1 show the percent volume increase of the paw 
after IM (intramuscular injection) of Zymosan (l mg/SO pl 
normal saline per paw) only. 
FIG. 1a shows that the percent (%) of volume increase of 
the paw of control animals which received IP (intraperito 
neally) 100 pl of propylene glycol (the vehicle of the drug) 
15 minutes prior to Zymosan administration. 
FIG. 2 shows the percentage volume increase of rat paw 
with time after IP administration of PC-l6. (3.6><l0_S rug/g 
of rat body weight which translates to a dose of 36 pg/kg of 
rat body weight P016) 15 min prior to IM in injection of 
Zymosan (1 mg/50 pl normal saline per paw). There is only 
a 20% maximum swelling at the 1.5 hour mark. 
FIG. 3 shows the percent volume increase of rat paw with 
time after IP injection of PC-l6 (at a dose of 360 pg/kg of 
rat body weight P016) 15 min prior to IM in injection of 
Zymosan (l mg/SO pl normal saline per paw). There is 
practically no swelling. 
FIG. 4 shows the impressive oedema reduction of rat paw 
treated with PC-l6 prior to the Zymosan injection compared 
with control. 
DESCRIPTION OF THE INVENTION 
Human leucocyte elastase (HLE) is a serine dependent 
enzyme which in its active site utilizes the so-called 
“charged-relay system”, a triad of amino acids -an aspartic 
acid, a histidine and a serine residue. A natural or a synthetic 
inhibitor should produce a tight binding with the active site 
which can lead to an increased rate of hydrolysis, producing 
inactive acylated enzyme. The rate of acylation and deacy 
lation of the inactive acylated enzyme determine the extent 
of inhibition. Elastin, a component of connective tissue, is 
present in virtually every organ of the body and is the natural 
substrate of HLE. The polypeptide chain of elastin consists 
of elastic areas alternating with inelastic areas. The elastic 
areas are composed of largely hydrophobic (non-polar) 
amino acids such as glycine, alanine, proline and valine. The 
inelastic areas are composed of polyalanine sequences with 
interspersed lysine residues. 
Based on the above, an effective inhibitor of elastase 
should meet the following requirements. It should be an 
ester that simulates the natural substrate elastin in incorpo 
rating aliphatic chains with similar hydrophobic character. 
Additionally it should be a good acylating agent so that it 
can form an acyl-enzyme complex in the serine residue of 
the active site with a low rate of deacylation. 
The l-phenyl—lH-tetrazole-S-thiol (D) (see scheme 1) is 
considered a good leaving group due to the thione-thiol 
tautomerization and this. should make the thiocarbamates 
good acylating reagents. The primary and secondary amine 
substituents with butyl, isopropyl, allyl, phenyl, ethyl-butyl, 
and diisopropyl were selected to test the requirement of HLE 
for a hydrophobic non polar residue in the substrate or 
inhibitor. 
The designed and synthesized compounds, described 
herein, include, but are not limited to, thiocarbamates con 
sisting of a primary or a secondary aliphatic amine and a 
l-phenyl-lH-tetrazole-S-thiol. The primary thiocarbamates 
5,539,123 
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N-butyl, l-phenyl-lH-tetrazole-S-thiocarbamate (1E), N-al 
lyl, 1~phenyl-lH-tetrazole-S-thiocarbamate (2E), N-isopro~ 
pyl, 1-phenyl-lH-tetrazole-S-thiocarbamate (3E), and 
N-phenyl, l-phenyl-lH-tetrazole-S-thiocarbamate (4E) 
were synthesized according to scheme I below. 
EXAMPLE 1 
In the ?rst reaction, the corresponding primary amine (A), 
(Scheme 1) reacts with excess of carbonyl chloride (phos 
gene) (B) in toluene to produce the corresponding isocyan 
ate (C) with concomitant release of hydrochloric acid. Then 
in the second reaction the isocyanate (C) reacts with excess 
of 1—phenyl-lH-tetrazole- 5-thiol (D) in methylene chloride 
to produce the corresponding primary thiocarbamates (E). 
The secondary thiocarbamates N-ethyl-N-butyl, l-phe 
nyl-lH-tetrazole-S-thiocarbamate (5E), and N, N-diisopro 
pyl, l~pheny1-lH-tetrazole-S-thiocarbamate (6E) were syn 
thesized according to scheme II below. 
EXAMPLE 2 
In the ?rst step the corresponding secondary amine (A), 
(Scheme II) reacts with excess of carbonyl chloride (phos 
gene) _(B) in toluene resulting in the production of the 
corresponding carbarnoyl chloride (C). In the second step 
the carbarnoyl chloride (C) reacts with excess of l-phenyl 
lH-tetrazole-S-thiol (D) to produce the corresponding sec 
ondary thiocarbamates (E). Both scheme I and scheme II 
result in good yields of white crystalline products with the 
exception of (SSE) which is a yellowish oil. 
SCHEME I 
Synthesis of Primary Thiocarbamates 
Scheme I 
O 
R 
(C) 
10 
25 
35 
40 
45 
6 
SCHEME I-continued 
Synthesis of Primary Thiocarbamates 
Scheme I 
N 
\ N Methylene 
N/ 
(C) (D) 
(XS) 
(E) 
R- EW. mp. °C. Yield % 
277.35 
261.30 
(1) 
(2) 
(3) 
C113 - crr2 - cu2 - CH2 — 
cu2 = cu — cr-r2 - 
61-62 
92-93 
75-80 
75-80 
CH3 263.32 89-90 70-75 
CH3 
(4) 297.33 120-121 60-65 
*in excess of the reagennt 
SCHEME II 
Synthesis of Secondary Thiocarbamates 
Scheme II 
(A) (B) (C) 
5,539,123 
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SCHEME II-continued 
Synthesis of Secondary Thiocarbamates 
Scheme II 
R N / ' R N / 
(C) (D) (E) 
(XS) 
R R‘ Ew. m.p. oc. Yield % 
(5) CH3 — CH2 — cr-r3 — CH2 ~— CH2 — CH2 305.39 011 40-45 
(6) CH3 CH3 305.41 105-106 45~50 
CH- CH 
cr-r; CH3 
*in excess of the reagent 
25 
An alternative method scheme In has been proposed and 
tested for the synthesis of our compounds based on the w. 
synthesis of oligopeptidyl carbamate esters as HLE inhibi- Alternative Synthesis of Thiocarbamates 
tors from our labs. 
30 If‘) N \ N Ii!) N \ N 
a) c1-c-c1+r1s-</ ll me—>c1—c-s—</ ll EXAMPLE 3 N -HCl N
(Xs)* N / 
According to scheme III in the ?rst reaction l-phenyl- (B) 
of hydrochloric acid. In the second reaction the l-phenyl 
lH-tetrazole'5-thi0chloroformate (C) reacts with the pri 
mary or secondary thiocarbamates (E). 
In practice scheme III has a disadvantage over scheme I 
and II. The crude product from the second reaction of (X8) 
scheme III is a reaction mixture which after recrystallization 
N / 
lH-tetrazole-S-thiol (A) reacts with excess of carbonyl 35 
chloride (phosgene) (B) in toluene to produce l-phenyl-IH 
tetrazole-S-thiochloroformate (C) with simultaneous release 
(A) (C) 
yields 80% of the urea (F) of the corresponding amine. (D) 
Puri?cation of the rest of the reaction mixture by silica gel 45 '(I) N \ 
?ash chromatography, results in poor yields of the desired / N CHCls 
thiocarbamate never exceeding 15-20%. This indicates that C1_c_s _< :11 ~HCI E E 
the major product of scheme III is the corresponding urea (F) N / 
and as a result the method was less preferred. 
50 
EXAMPLE 4 
(C) 
Stability of N-n-Butyl, 55 0 N\ 
l-Phenyl-lH-Tetrazole-S-Thiocarbamate (1E) in H / N 
Excess of Methanol with Normal Phase HPLC CHB-CHZ—CHZ—CHZ—NH—C—S % {If 
/ 
A separation between (1E) and (D) was achieved in (E) N 
normal phase chromatography conditions with a PARTISIL- 60 
50 normal phase silica column and 0.05% acetic acid in 
methylene chloride mobile phase. The ?ow was maintained 
at 1 ml/min, and a KRATOS variable UVdetector at 265 nm 
was used. Two separate experiments were conducted under 
the above conditions in which the stability of (1B) was 
5,539,123 
-continued 
SCHEME III 
0 
CH3—CH2--Cl-I2—~CI-I2—-Nl-I—2—NH——CH2—CH2—-CH2—CH3 
(F) main product 
*in excess of the reagent 
monitored in excess of methanol. In the ?rst experiment the 
disappearance of (IE) was monitored with time in excess of 
5 
10 
10 
EXAMPLE 5 
Inactivation of Human Leucocyte Elastase by the 
Primary and Secondary Thiocarbamates 
The novel compounds synthesized (1E—6E, Formula 1), 
were evaluated for their ability to inhibit the HLE-catalyzed 
hydrolysis of N-Methoxysuccinyl~L-Ala‘L-Ala'L-Pro-L 
Val-p-nitroanilide and were found to exhibit time dependent 
inhibition of this enzyme. Therefore, second order rate 
constants (km/I, M*1 s“), (Izconcentration inhibitor molar) 
shown in Formula 1, were determined by following the 
inactivation of the enzyme for 2 hours as 
FORMULA 1 
Inhibition of Thiocarbamate compounds against HLE 
*No inhibitory activity 
methanol and from the slope of the logarithmic curve of the 
concentration of (1E) vs. time the pseudo?rst order rate 
constant is determined at 1.65X10_3 hr_1. 
In the second experiment again the disappearance of the 
thiocarbamate (1E) is measured by monitoring now the 
appearance of l-phenyl-1H-tetrazole~5-thiol (D) with time 
and from the slope of the logarithmic curve vs time we 
determine the pseudo?rst order rate constant which is 1.71X 
10—3 hr_1. 
The above two experiments indicate that (IE) is con 
sumed at the same rate as the thiol tetrazole (D) is produced. 
The thiol tetrazole (D) is exclusively produced from the 
degradation of the thiocarbamate with methanol. In other 
words (1E) reacts with methanol to give thiol tetrazole (D) 
and most probably N~n-butyl, methylcarbamate which can 
not be detected under the above conditions. The half life as 
calculated from the pseudo?rst order rate constants is 17 
days indicating that (IE) is a fairly stable compound in 
excess of methanol. 
45 
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described in the experimental section. Generally, the com 
pounds always in excess are incubated for di?ierent time 
intervals with the enzyme and at the end of the incubation 
interval the substrate is added and the absolute remaining 
activity of the enzyme is measured as described in the 
enzymatic assay of the experimental section. The results are 
plotted as % of relative remaining activity vs time which is 
the absolute remaining activity in the presence of inhibitor 
divided by the absolute remaining activity of the free 
enzyme in absence of inhibitor for the same time interval. 
All of the studied inhibitors except the phenyl thiocar 
bamate (5B) show initially a pseudo?rst order rate pro?le 
which ends in zero order at longer times. The phenyl 
thiocarbamate (5E) shows only pseudo?rst order rate pro?le. 
The enzyme appears to react with the inhibitor in a pseud 
o?rst order manner to produce a modi?ed enzyme which is 
partially active and maintains a fractional activity (P) com 
pared to the original activity. In such a case a semilog plot 
of the relative remaining activity (A/Ao) vs time would 
describe a curve approaching the fractional activity (P) at 
longer times whereas a semilog plot of (A/Ao-F)/(l~F) vs 
5,539,123 
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time will be linear with a slope equal to the kabs, 
pseudo?rst order rate constant (equation 2). 
The inactivation of HLE enzyme appears to involve the 
chemical modi?cation of one residue on the enzyme and the 
pseudo?rst order rate constant k0,” divided by the concen 
tration of the inhibitor (I) can be used as a measure of the 
inhibitory activity of the compounds (equation 3). It follows 
that the larger the number of KIM/I (Ksec) the greater the 
inhibiting capacity of the compound. 
the 
O 
H 0 
CHzOWCLNAYIIQ (I) I \N/ s ‘ 1 N \n/ 
O H O 0 
\ 
c=o 
Thus, compound N-n-butyl, l-phenyl-lH-tetrazole-S 
thiocarbamate (1E) exhibits the highest inhibitory activity 
(kamjl=2.l><l05 M_1S_1) indicating the trend that straight 
chain nonpolar aliphatic substituents are essential for high 
activity. Indeed the N-allyl, l-phenyl-lH-tetrazole-S-thio 
carbamate (2E) with the polar straight chain due to the 
double bond has the second highest inhibitory activity of all 
thiocarbamates (ka,,s/I:6.lXl04 M'1s_1). 
Furthermore the most polar aromatic N-phenyl, l-phenyl 
lH-tetrazole-S-thiocarbamate (4E) is one of the least active 
thiocarbamates (k0b:/I:l.9><l 02 M‘1s_1) with activity simi 
lar to the N-ethyl-N-butyl, l-phenyl-lH-tetrazole-S-thiocar 
bamate (5E) (kob:/I=l.8><l0 MAS-1). The N-isopropyl, 
l-phenyl-lH-tetrazole-S-thiocarbamate (3E) (k0bs/I=3.3x 
l03 M“1s_1) is 10 times more active than (4E) and N, 
N-diisopropyl, l-phenyl-lH-tetrazole-S-thiocarbamate (6E) 
has no inhibitory activity against HLE. 
The fact that secondary thiocarbamates have the least or 
no activity along with the low activity of (3E) indicates a 
second important trend, the degree of branching of the side 
chain. The inhibitory activity decreases as the degree of 
branching on the side chain increases. None of the corre 
sponding amines (1A, 2A, 3A, 4A, 5A and 6A) nor l~phe 
nyl-lH-tetrazole-S-thiol (D) inhibited HLE. 
When compared to the oligopeptidyl carbamate speci?c 
inhibitor of HLE (PCl), synthesized previously in our labs, 
with k‘,l,S/I=3.3><lO4 M'ls'1 only N-n-butyl, l-phenyl-lH 
45 
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tetrazole-S-thiocarbamate (1E), and N-allyl, l~phenyl-lH 
tetrazole-5-thiocarbamate (4E) were found 10 and 2 times 
more potent, respectively. Formula 2 shows the structure of 
comparative compound PC-l and PC-5. 
Finally the low molecular weight thiocarbamates provide 
an advantage over their oligopeptidyl predecessors ?rstly 
due to their simple one or two step synthesis, secondly due 
to their improved or comparable 
FORMULA 2 
0 
CH2 
activity and lastly due to their potential increased oral 
bioavailability. 
EXAMPLE 6 
Synthesis of Primary and Secondary 
Thiocarbamates 
Proton NMR spectra were recorded on a Varian VXR-300 
NMR spectrometer with tetramethylsilane as internal stan 
dard (5 scale) in CDCI3. Elemental analyses were conducted 
by the Atlantic Microlab, Inc., Atlanta, Ga. and the results 
were within 0.4% of the theoretical values. 
IR. spectra were determined in KBr discs, as Nujol mulls 
or liquid ?lms on a Perkin Elmer 567 spectrophotometer. 
Melting points were determined on a Fisher-Hohns Unimelt 
apparatus and are uncorrected. Reactions were routinely 
followed by thin layer chromatography (TLC) using What 
man K67 silica gel plates, and spots were visualized either 
by UV irradiation at 254 nm or by iodine chamber. 
Compounds (1E), (3E), and (6E) were recrystallized from 
2~propanol and water, (4E) was recrystallized from acetone 
and water, (2E) was recrystallized from isopropyl ether, and 
?nally ?ash chromatograpy for the puri?cation of (SE) was 
performed with Alumina gel. 
5,539,123 
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Ir and NMR spectra were consistent with the assigned 
structures of all new compounds and intermediates. The 
reported yields were generally the result of a single experi 
ment and were not optimized 
EXAMPLE 7 
Method A: Synthesis of Primary Thiocarbamates 
N-n-Butyl, l-Phenyl*lH-tetrazole-S-thiocarbamate (1E). 
(Scheme I) 
a) Synthesis of n-butylisocyanate (1C). 
A solution of n-butylamine (1A) 3.7 g in 50 ml toluene 
was added in an excess of 33.7 ml carbonyl chloride solution 
(phosgene) (Fluka Chemicals) (B) solution 20% in toluene 
over a period of 1 hour at below —15° C. and it was left at 
room temperature stirring overnight. The excess of carbonyl 
chloride was removed by a stream of dry air, and the 
precipitated n-butylamine hydrochloride was ?ltered and 
washed with chloroform. The combined ?ltrate and wash 
ings were then distilled under vacuum and the distillates 
were characterized by IR. The distillate with the largest 
characteristic peak at 2360 cm-1 was the n-butylisocyanate 
(1C) and it was used as is to the next step. 
b) Synthesis of N-n-butyl, l-phenyl~lH-tetrazole-5 
hiocarbamate (1E). 
1.63 ml n-butylisocyanate (1C) from the previous step or 
purchased commercially (Aldrich Chemicals) was added 
over a period of 1 hour in an excess of a 1~phenyl-1H 
tetrazole-5~thiol (D) (Aldrich Chemicals) solution 3.1 g in 
120 ml methylene chloride stirring at room temperature and 
it was left to react overnight. The reaction then was con 
centrated in a rotary evaporator and triturated with hexane to 
give a crude white solid which was reconcentrated three 
times more with hexane. The crude solid was slurred in rnd 
2-propanol and heated at re?ux until it was in solution. After 
?ltering the hot solution the ?ltrate was cooled in an ice bath 
for 20 min and water was added until permanent cloudiness 
appeared. Then it was reheated at re?ux until it was again in 
solution. 
The solution was allowed to cool to 20°—25° C. for 12 
hours and aged another 12 hours at 0°—5° C. The precipitated 
white crystalline solid was ?ltered and dried to afford 3.1 g 
(80% yield) of (IE), mp 61°-62° C., proton NMR: 1.0 
(t,3H), 1.48 (sext., 2H), 1.69 (p, 2H), 3.57 (q, 2H), 7.6—7.77 
(m, 5H), 9.7 (s, 1H), 13C NMR: 12.8, 20.0, 31, 40.8, 124.6, 
129.8, 130.5, 134, 146, 162.3. Elemental analysis found 
(CIZHUNSOS) C: 51.88, H: 5.45, N: 25.25, S: 11.57. 
The following compounds were synthesized by analogous 
procedures: N-allyl, l~phenyl~lH-tetrazolea5-thiocarbamate 
(2E) white crystalline solid from the reaction of allylisocy 
anate (2C) (Aldrich Chemicals) with l-phenyl-lH-tetrazole 
5-thiol (D), was recrystallized from isopropyl ether, yield 
80%, mp 92°-93° C.,1H NMR: 3.8 (q, 2H), 5.1 (d,1HO, 5.3 
(d, 1H), 5.9 (rn, 1H), 7.4—7.7 (m, 5H). Elemental analysis 
(CHHHNSOS) C: 50.55, H: 4.22, N: 26.89, S: 12.25. 
N -isopropyl, l-phenyl-1H-tetrazole-S-thiocarbarnate (3E) 
white crystalline solid from the reaction of isopropylisocy 
anate (3F) (IR: 2260 cm“), prepared as described above 
from phosgene and isopropyl amine, or purchased commer 
cially (Aldrich Chemicals), and l-phenyl-lH-tetrazole-S 
thiol (D) was recrystallized from isopropyl alcohol and 
water, yield 75%, mp 89°—90° C., 1H NMR 1.5 (d, 6H), 3.48 
(m, 1H), 7.6-7.8 (m, 5H). Elemental analysis (CUHBNSOS) 
C: 50.16, H: 4.97, N: 26 . 65, S: 12.23. 
N-phenyl, l-phenyl-lH-tetrazole-S-thiocarbamate (4E) 
white crystalline solid from the reaction of phenylisocyanate 
(4C) (Aldrich Chemicals) and 1~phenyl-lH-tetrazole-S-thiol 
30 
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(D), was recrystallized from acetone water, yield 63%, mp 
120°—121° C., 1H NMR: 7.4—8.0 (rn, 10H). Elemental 
analysis (CMHUNSOS) C: 56.47, H: 3.7, N: 23.5, S: 10.26. 
EXAMPLE 8 
Method B: Synthesis of Secondary Thiocarbamates 
N-Ethyl-N-n-butyl, 1 -phenyl- 1 H~tetrazole-5-thiocarbam 
ate (5E). (Scheme H) 
a) Synthesis of Ethyl, n-butyl carbamoyl chloride (5C). 
4.5 ml ethyl, butylarnine were added in an excess of 18 ml 
carbonyl chloride (phosgene) (Fluka Chemicals) (B) solu 
tion 20% in toluene over a period of 1 hour at below —15° 
C. and it was left at room temperature to react overnight. The 
excess of carbonyl chloride was removed by a stream of dry 
air and the precipitated ethyl, butylarnine hydrochloride was 
?ltered and washed with chloroform. The‘ ?ltrate and the 
washings were then distilled under vacuum and the distil 
lates were characterized by IR, 1H NMR and 13C NMR. The 
distillate with the following characteristics was (5C) and it 
was used without any further puri?cation to the next step. 
IR: strong carbonyl peak at 1738 cm“, and strong aliphatic 
peak at 2950 cm_1. 1H NMR: 0.96 (t, 3H), 1.22 (t, 3H), 1.34 
(rn, 2H), 1.61 (rn, 2H), 3.39 (m, 4H). 13C NMR: 12.7, 13.7, 
19.9, 30, 45.5, 50, 148.8. 
b) Synthesis of N-Ethyl-N-n-butyl, l-phenyl-lH-tetra 
zole-5-thiocarbamate (SE). 
5.4 ml ethyl, n-butyl carbamoyl chloride (5C) from the 
previous step was added over a period of half hour in an 
excess of l-phenyl-lH-tetrazole-S-thiol (D) (Aldrich 
Chemicals) solution 7.13 g in 240 I111 methylene chloride 
stirring at room temperature and it was left to react over 
night. The reaction mixture was then concentrated in a rotary 
evaporator to give 5 g of an oily residue. The product was 
puri?ed by alumina gel ?ash chromatography with 5% 
methanol in methylene chloride and the fractions collected 
were monitored by TLC in UVat 254 nmto afford 4.2 g, 42% 
yield of the oily product N-ethyl-N-n-butyl, l-phenyl-lH 
tetrazole-S-thiocarbamate (5E) after evaporation of the sol 
vent. 1H NMR: 0.8-1.6 (m, 10H), 3.3 (m, 4H), 7.56 (m, 5H). 
13C NMR: 12.7, 13.7, 19.8, 30.5, 43.5, 48, 125.1, 128.3, 
129.3, 130.5, 134, 147, 159. Elemental analysis 
(C14H19N5OS) C: 55.05, H: 6.34, N: 22.99, S: 10.57. 
In a similar manner the following compound was synthe 
sized: 
N,N-diis0propyl 1-phenyl-lH-tetrazole-S-thiocarbamate 
(6E) is a white crystalline solid produced from the reaction 
of diisopropyl carbamoyl chloride (6C) (Aldrich Chemicals) 
and l-phenyl-lH~tetrazole-5-thiol (D), was recrystallized 
from a mixture of isopropyl alcohol and water or a mixture 
of dimethyl forrnarnide and water, yield 47%, 1H NMR: 1.2 
(d, 12H), 3.4 (m, 1H), 3.85 (rn, 1H), 7.45-7.6 (m, 5H). 
Elemental analysis (C14H19N5OS) C: 55.05, H: 6.30, N: 
22.91, S: 10.42. 
EXAMPLE 9 
Method C: Alternative Synthesis of Thiocarbamates 
N-n-butyl, 1-phenyl—lH-tetrazole-5~thiocarbarnate (5E) 
(Scheme HI). 
a) Synthesis of 1-Phenyl-1H-tetrazole-S-thiochlorofor 
mate (C). 
A solution of 4 g 1-phenyl-lH-tetrazole-S-thiol (A) in 90 
ml tetrahydrofurane was added in an excess of 15.5 ml 
carbonyl chloride solution (phosgene) (Fluka Chemicals) 
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(B) 20% toluene, over a period of half hour at below —20° 
C. and it was left at room temperature stirring overnight. The 
excess of carbonyl chloride was removed with a stream of 
dried air and the solvent was evaporated in a rotary evapo 
rator. The solid residue was recrystallized from ethylacetate 
and hexane. The crude solid was heated at re?ux with 
ethylacetate until it was all dissolved and after warm ?lter 
ing it was cooled in an ice bath. Then hexane was added until 
permanent turbidity was formed and was reheated at re?ux 
until it was again in solution. 
The solution was allowed to cool and age at room 
temperature over a period of 2 hours and at 0°~5° C. for 
another 4 hours. The precipitated crystalline solid was 
?ltered and dried to afford 3.2 g of l-phenyl-lH-tetrazole 
5-thiochloroformate (C) (57% yield), mp l2l°—l22° C., IR: 
1715 cm“1 carbonyl, 3060 cm-1 aromaticity, 13C NMR: 125, 
130, 131.5, 133, 144, 176.5, 1H NMR: 7.4 (m, 2H), 7.6 (m, 
3H). 
b) Synthesis of N-n-butyl, l-phenyl-lH-tetrazole-S 
thiocarbamate (SE). 
0.93 ml n-butyl amine (5D) (Aldrich Chemicals) in 20 ml 
methylene chloride was added in an excess of 2.5 g l-phe 
nyl-1H-tetrazole-5-thiochloroformate (C) solution in 120 ml 
methylene chloride over a period of half hour and it was left 
stirring at room temperature to react overnight. The reaction 
mixture was concentrated in a rotary evaporator and tritu 
rated with petroleum ether resulting in crude yellowish solid 
after evaporation of the solvent. The crude solid was recrys 
tallized by a mixture of acetone and water with a procedure 
similar to that described in the previous step to afford 0.98 
g of a white crystalline product, mp 70°—71° C., which was 
identi?ed to be N,N‘-di-n-butyl, urea (5F) and not the 
desired product (5E). Yield 80% IR: 1620 cm-1 carbonyl 
(up?eld characteristic for ureas), 3140 and 3325 cm-lN-H 
stretching vibration. 1H NMR: 0.93 (t, 3H), 1.35 (m, 2H), 
1.48 (m, 2H), 3.15 (m, 2H), 4.22 (s, 1H). 
In a second attempt of the same reaction after discarding 
the triturated from petroleum ether solid urea (5F) the ?ltrate 
was introduced into a silica gel ?ash chromatography col 
umn and washed with chloroform. Fractions were collected 
and detected by TLC in UVat 254 nm. The fractions corre 
sponding to (SE) were collected and characterized as 
described at method A to give 39 mg of (SE) 15% yield. 
Method C was less preferred. 
EXAMPLE 1O 
Enzyme Inhibition Kinetics 
Human leucocyte elastase from human sputum was pur 
chased from elastin corporation. Hepes, 4'(2-hydroxyethyl) 
l-piperazineethanesulfonic acid, was purchased from Ald 
rich Chemical Co. (Milwaukee, Wis.). Substrate 
N-Methoxysuccinyl-L-Ala-L-Ala-L~Pro-L-Val-p-nitroanil 
ide was purchased from Sigma Chemicals. Absorbance was 
measured with a VARIAN CARY~220O spectrophotometer 
at 410 nm. 
a) Enzyme Assay. 
2.9 ml Hepes bu?er (0.1M Hepes, 0.05M NaCL, 10% 
Dimethyl Sulfoxide, adjusted with 6N NaOH at ph=7.5), 50 
pl of inhibitor solution always in excess of enzyme in 
Dimethyl sulfoxide, are placed in each of two 3 ml quartz 
cuvettes. 5 pl of acetate buffer (0.05M Sodium Acetate 
adjusted with 6N HCl to ph:5.5) is added to the reference 
cuvette, and the cuvette is shaken for 15 seconds to mix the 
solution. 5 pl of HLE 3.7><10_5M in acetate buffer is added 
to the sample cuvette and the cuvette is shaken for 15 
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seconds. Both cuvettes were placed in the jacketed cuvette 
holders of the spectrophotometer and incubated at 25° C. for 
a ?xed time interval up to 2 hours (Incubation periods of 3, 
4, 5, 7, 10, 15, 20, 30, 45, 60, 90 and 120 minutes were 
used). 
Shortly before the incubation period ends, the cuvettes are 
balanced at 410 nm. 50 pl of HLE substrate 2.8><lO_2M in 
Dimethyl sulfoxide is added to both the reference and 
sample cuvette, with addition to the sample cuvette marking 
the end of the incubation time. The cuvettes are shaken for 
15 seconds and the absorbance is recorded at 410 nm at 1 
min, 2 min and 3 min after addition of substrate. A control 
.in which 50 pl of dimethyl sulfoxide used to dissolve the 
inhibitor is added in its place, is done in the same manner as 
above for each incubation period. 
The ?nal Dimethyl sulfoxide concentration never 
exceeded 12% v/v. Absorbance of sample is the absolute 
remaining activity of HLE (A), and absorbance of control is 
the total activity of HLE (Ao). 
% Relative Remaining Activity=(A/Ao)><l00 
The % relative remaining activity of the HLE for each‘ 
inhibitor is plotted against the time of incubation and from 
the slope of the sernilog plot the km is determined. 
b) Modelling the inhibition. 
Enzyme kinetics. 
E kobs ; E. 
The enzyme (E) reacts with the excess of inhibitor (I) in a 
pseudo?rst order rate process to produce the modi?ed 
enzyme (E') which is partially active and has fractional 
activity F compared to the original activity A0. 
The equation that describes this model is: 
A/A0=(1—F)e_K°"s‘+F (equation 1) 
Rearranging results in a linear relationship 
Ln ((A/A0)—F/l-F)=—k,,,,,t (equation 2) 
A semilog plot results in a straight line with slope=kaby the 
pseudo?rst order rate constant 
ksec:kabs/I (equation 3) 
The km is the second order independent rate constant that 
is used to compare the inhibitory activity of the compounds 
against HLE. 
Summary of Results with Compound PC-l6 
Attached are results which show strong evidence of the 
ability of an exemplary compound of the present invention, 
compound PC-16, to act as an antiarthritic drug in the 
Zymosan-induced arthritis, an acceptable animal model of 
chronic proliferative arthritis in the rat. The rat is an accept 
able experimental animal model for correlation to human 
utility, and the present results constitute excellent proof for 
the value of the compounds of the present invention as 
elastase inhibitors. 
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Compound PC-16 
Protocol of Arthritic Study 
A reversible arthritic condition was induced according to 
known procedures for the Zymosan-induced arthritis (See J. 
P. Tarayre, A. Delphon, et al., Pharmacological studies in 
Zymosan in?ammation in rats and mice, I: Zymosan-induced 
paw edema in rat and mice, Pharmacological Research, 21, 
(#4) 375-384 (1989); Takuo Sato, Yoshitaka Ino, et al., 
Inhibitory effects of a novel synthetic protease inhibitor 
(PUT-175), on the paw edema in rats and Zymosan-induced 
compliment activation in vitro, Japan J. Pharmacol., 
42,587-589 (1986); David K. Gremmell, et al., Comparative 
effects of drugs on four paw edema models on the rat, Agents 
and Actions 4, (#1) 107-116 (1979); and D. C. Keystone, et 
al., Zymosan-induced arthritis: A model of chronic prolif» 
erative arthritis following activation of the alternative path 
way of compliment, Arthritis and Rheumatism 20 (#7) 
1396-1401 (1977)). 
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Each rat (250 g each) was kept in a restraining cage with 
light ether anesthesia until the administration of the drug. 
The procedure involves the intramuscular (IM) injection of 
1 mg of Zymosan in 50 pL (rnicroliters) of normal saline in 
the pad of a hind paw of the rat. Swelling becomes evident 
within 20 minutes and reaches a maximum within 1.5 hours. 
The swelling disappears after 24 hours. In the Figures the 
reversal to normal size of the paw within 24 hours is not 
shown. The degree of swelling is measured by a water 
displacement method and the percent (%) of volume 
increase of the paw is plotted against time (see J. P. Tarayre, 
A. Delphon, et al., Pharmacological studies in zymosan 
in?ammation in rats and mice. 1: Zymosan-induced paw 
edema in rat and mice, Pharmaco-logical Research, 21, (#4) 
375-384 (1989); Takuo Sato, Yoshitaka Ino, et al., Inhibitory 
effects of a novel synthetic protease inhibitor (PUT-175), on 
the paw edema in rats and Zymosan-induced compliment 
activation in vitro, Japan J. PharmacoL, 42, 587-589 
(1986)). 
FIG. 1 shows the percent (%) of volume increase of the 
paw after I.M. injection of Zymosan (1 mg/paw in 50 pl 
normal saline). Control was conducted by injecting LP. 100 
pl of propylene glycol (the vehicle) 15 min. prior to Zymo 
san administration. FIG. 1a shows the percent (%) of 
volume increase of the paw in control animals with time 
which reaches a value of 60% within 1.5h. Data from tables 
1 and 1a are plotted in FIGS. 1 and 1a respectively. 
TABLE 1 
Zymosan In?ammation in Rats 
Experiment #1 Experiment #2 Experiment #3 
Time Volume % Volume Volume % Volume Volume % Volume Mean of 3 Standard 
(min) (ml) Increase (ml) Increase (ml) Increase experiments Deviation 
0 1.53 0.0 1.53 0.0 1.65 0.0 0.00 0.00 
10 1.74 13.7 1.74 13.7 1.98 20.0 15.82 3.62 
14 1.83 19.6 1.83 19.6 2.00 21.0 20.07 0.80 
16 1.86 21.6 1.86 21.6 2.03 23.0 22.05 0.83 
20 1.78 16.3 1.83 19.6 2.05 24.0 19.98 3.84 
25 1.84 20.3 1.84 20.3 2.05 24.0 21.51 2.16 
31 1.91 24.8 1.91 24.8 2.06 25.0 24.89 0.09 
35 1.90 24.2 1.90 24.2 2.08 26.0 24.79 1.05 
40 1.96 28.1 1.96 28.1 2.10 27.0 27.74 0.64 
45 1.81 18.3 1.95 27.5 2.11 28.0 24.58 5.45 
50 1.83 19.6 1.94 26.8 2.13 29.0 25.14 4.91 
55 1.89 23.5 1.93 26.1 2.13 29.0 26.22 2.74 
60 1.90 24.2 1.95 27.5 2.15 30.0 27.21 2.92 
70 2.04 33.3 2.04 33.3 2.19 33.0 33.22 0.19 
77 2.05 34.0 2.05 34.0 2.21 34.0 33.99 0.01 
80 1.98 29.4 2.01 31.4 2.23 35.0 31.93 2.84 
86 2.11 37.9 2.11 37.9 2.26 37.0 37.61 0.52 
91 2.09 36.6 2.09 36.6 2.28 38.0 37.07 0.81 
98 2.08 35.9 2.08 35.9 2.28 38.0 36.63 1.18 
105 2.09 36.6 2.09 36.6 2.29 39.0 37.40 1.38 
110 1.89 23.5 2.07 35.3 2.28 38.0 32.27 7.69 
115 1.92 25.5 2.06 34.6 2.26 37.0 32.38 6.08 
120 2.05 34.0 2.05 34.0 2.24 36.0 34.66 1.16 
127 1.92 25.5 2.03 32.7 2.23 35.0 31.06 4.96 
132 2.05 34.0 2.05 34.0 2.21 34.0 33.99 0.01 
143 2.08 35.9 2.08 35.9 2.23 35.0 35.63 0.55 
170 2.05 34.0 2.05 34.0 2.21 34.0 33.99 0.01 
213 2.10 37.3 2.01 31.4 2.18 32.0 33.54 3.23 
240 1.92 25.5 1.92 25.5 2.08 26.0 25.66 0.29 
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TABLE 121 
Zymosan Induced In?ammation in Rats 
Control Experiment with solvent (0.1 ml Propylene Glycol) 
Experiment #1 Experiment #2 Experiment #3 
Time Volume % Volume Volume % Volume Volume % Volume Mean of 3 Standard 
(min) (ml) Increase (m1) Increase (ml) Increase experiments Deviation 
0 1.67 0.00 1.80 0.00 1.85 0.00 0.00 0.00 
5 1.80 7.78 1.94 8.00 1.99 7.67 7.82 0.17 
10 1.83 9.60 1.97 9.45 2.03 9.54 9.53 0.08 
15 1.96 17.4 2.12 17.9 2.17 17.1 17.5 0.41 
20 2.15 28.7 2.30 27.6 2.39 29.1 28.5 0.78 
25 2.30 37.7 2.49 38.2 2.55 37.8 37.9 0.26 
30 2.22 32.9 2.51 39.6 2.60 40.5 37.7 4.13 
40 2.42 44.9 2.62 45.3 2.68 45.1 45.1 0.19 
45 2.49 49.1 2.67 48.6 2.77 49.5 49.1 0.45 
50 2.48 48.5 2.68 49.1 2.75 48.8 48.8 0.30 
55 2.62 56.9 2.80 55.4 2.87 55.3 55.9 0.89 
60 2.62 56.9 2.82 56.7 2.91 57.5 57.0 0.42 
65 2.56 53.3 2.83 57.4 2.92 58.1 56.3 2.60 
75 2.64 58.1 2.85 58.5 2.92 58.1 58.2 0.24 
80 2.51 50.3 2.87 59.6 2.96 60.2 56.7 5.55 
85 2.65 58.7 2.87 59.3 2.94 58.8 58.9 0.33 
90 2.63 57.5 2.86 58.9 2.93 58.2 58.2 0.71 
105 2.67 59.9 2.86 58.8 2.92 57.8 58.8 1.04 
110 2.71 62.3 2.87 59.3 2.95 59.6 60.4 1.64 
120 2.65 58.7 2.85 58.5 2.92 57.6 58.3 0.58 
130 2.61 56.3 2.83 57.1 2.90 56.6 56.7 0.41 
140 2.54 52.1 2.73 51.5 2.80 51.4 51.7 0.38 
150 2.48 48.5 2.67 48.6 2.74 47.9 48.3 0.38 
160 2.45 46.7 2.65 47.0 2.70 45.8 46.5 0.63 
170 2.41 44.3 2.60 44.4 2.67 44.5 44.4 0.09 
180 2.36 41.3 2.56 42.3 2.65 43.0 42.2 0.85 
190 2.36 41.3 2.55 41.5 2.60 40.5 41.1 0.53 
200 2.42 44.9 2.51 39.7 2.57 38.8 41.1 3.30 
210 2.30 37.7 2.47 37.2 2.54 37.1 37.3 0.34 
220 2.25 34.7 2.43 35.0 2.50 35.3 35.0 0.28 
230 2.18 30.5 2.33 29.4 2.38 28.7 29.5 0.93 
240 2.21 32.3 2.35 30.5 2.41 30.2 31.0 1.16 
In the experimental procedure the drug [PC-16, 9 g/rat When 36 ttg/kg of compound PC-16 (FIG. 2, shows 
(FIG. 2) or 90 pg/rat (FIG. .3)] 1S dISSOIVed 1“ 100 of 36x10‘5 mg/g of rat body weight which translates to adose 
propylene glycol and is 11'1J6C1CC1 IP to the rats. Fifteen 40 f 36 [k , _ _ d IP h (7 1 
minutes later the Zymosan (1mg/50 pL of normal saline) 0 pg 9 18 “116cm to rats t 6 percent ( 0) v0 “me 
solution is injected IM into the paw of the rats. The degree increase is only 20% at the 1.5 hour mark. This means that 
of swelllng is. subsequently measured at various time mter- the swelling was reduced from 60% to 20% with 36 l1g/kg 
vals for a penod of 24 hours and 18 reported up to 4 hours‘ of compound PC-l6. (see FIG. 2 which plots data of Table 
45 
DETAILED DESCRIPTION OF THE FIGURES 
FIGS. 1 and 1a show that the percent (%) of volume 
increase of the paw of the rats reaches a value of 60% within 
1.5 hours. 
2 below). 
TABLE 2 
Zymosan Induced In?ammation in Rats 
Treatment with PC16 (3.6 x 10‘5 mg/g of Rat Body Weight) 
Experiment #1 Experiment #2 Experiment #3 
Time Volume % Volume Volume % Volume Volume % Volume Mean of 3 Standard 
(min) (ml) Increase (ml) Increase (m1) Increase experiments Deviation 
0 1.94 0.00 1.89 0.00 1.65 0.00 0.00 0.00 
10 2.17 11.9 2.14 13.2 1.84 11.5 12.2 0.91 
20 2.26 16.5 2.18 15.3 1.93 17.1 16.3 0.89 
30 2.29 18.0 2.20 16.4 1.94 17.5 17.3 0.84 
40 2.30 18.6 2.24 18.5 1.97 19.3 18.8 0.44 
50 2.31 19.1 2.26 19.6 1.96 18.8 19.1 0.39 
60 2.32 19.6 2.26 19.6 1.97 19.4 19.5 0.11 
65 2.33 20.1 2.26 19.6 1.98 19.8 19.8 0.26 
70 2.33 20.1 2.25 19.0 1.99 20.7 20.0 0.84 
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TABLE 2-continued 
Zymosan Induced In?ammation in Rats 
Treatment with PC16 (3.6 X 10‘5 mg/g of Rat Body Weight) 
Experiment #1 Experiment #2 Experiment #3 
Time Volume % Volume Volume % Volume Volume % Volume Mean of 3 Standard 
(min) (ml) Increase (ml) Increase (ml) Increase experiments Deviation 
80 2.30 18.6 2.31 22.2 1.99 20.7 20.5 1.84 
95 2.29 18.0 2.30 21.7 1.97 19.4 19.7 1.85 
100 2.29 18.0 2.23 18.0 1.98 19.8 18.6 1.03 
105 2.30 18.6 2.23 18.0 1.96 18.6 18.4 0.34 
115 2.29 18.0 2.22 17.5 1.95 18.3 17.9 0.43 
120 2.30 18.6 2.21 16.9 1.94 17.6 17.7 0.82 
130 2.28 17.5 2.23 18.0 1.94 17.6 17.7 0.25 
135 2.28 17.5 2.23 18.0 1.94 17.6 17.7 0.25 
145 2.30 18.6 2.22 17.5 1.93 17.1 17.7 0.76 
150 2.26 16.5 2.17 14.8 1.91 15.5 15.6 0.84 
160 2.23 14.9 2.18 15.3 1.90 15.2 15.2 0.20 
175 2.23 14.9 2.17 14.8 1.87 13.5 14.4 0.80 
190 2.16 11.3 2.16 14.3 1.85 12.3 12.6 1.50 
200 2.22 14.4 2.14 13.2 1.85 12.3 13.3 1.07 
205 2.16 11.3 2.21 16.9 1.85 12.2 13.5 3.01 
210 2.21 13.9 2.17 14.8 1.85 12.2 13.6 1.33 
220 2.20 13.4 2.16 14.3 1.87 13.1 13.6 0.62 
225 2.19 12.9 2.12 12.2 1.85 12.2 12.4 0.41 
240 2.17 11.9 2.13 12.7 1.84 11.6 12.1 0.57 
At a dose of 360 pg/kg of compound PC-16 there is 
practically no swelling (see FIG. 3 which plots data of Table 
3 below). 
TABLE 3 
Zymosan Induced In?ammation in Rats 
Treatment with PC16 (3.6 X 1074 mg/g of Rat Body Weight) 
Experiment #1 Experiment #2 Experiment #3 
Time Volume % Volume Volume % Volume Volume % Volume Mean of 3 Standard 
(min) (ml) Increase (ml) Increase (1111) Increase experiments Deviation 
0 1.80 0.00 1.85 0.00 1.65 0.00 0.00 0.00 
5 1.82 1.11 1.86 0.54 1.67 1.02 0.89 0.31 
10 1.83 1.67 1.87 1.08 1.68 1.55 1.43 0.31 
15 1.83 1.67 1.87 1.08 1.68 1.55 1.43 0.31 
20 1.83 1.67 1.88 1.62 1.68 1.55 1.61 0.06 
30 1.84 2.22 1.89 2.16 1.69 2.18 2.19 0.03 
40 1.84 2.22 1.90 2.70 1.69 2.18 2.37 0.29 
45 1.81 0.56 1.90 2.70 1.70 2.75 2.00 1.25 
50 1.83 1.67 1.90 2.70 1.70 2.75 2.37 0.61 
55 1.85 2.78 1.91 3.24 1.70 2.75 2.92 0.28 
60 1.85 2.78 1.91 3.24 1.70 2.75 2.92 0.28 
75 1.86 3.33 1.91 3.24 1.71 3.44 3.34 0.10 
80 1.86 3.33 1.92 3.78 1.71 3.44 3.52 0.24 
85 1.86 3.33 1.92 3.78 1.71 3.44 3.52 0.24 
90 1.86 3.33 1.92 3.78 1.71 3.44 3.52 0.24 
100 1.84 2.22 1.93 4.32 1.71 3.44 3.33 1.06 
110 1.86 3.33 1.94 4.86 1.70 2.75 3.65 1.09 
120 1.86 3.33 1.94 4.86 1.71 3.50 3.90 0.84 
125 1.85 2.78 1.94 4.86 1.71 3.50 3.71 1.06 Y 
130 1.84 2.22 1.93 4.32 1.71 3.50 3.35 1.06 
145 1.85 2.78 1.94 4.86 1.71 3.50 3.71 1.06 
150 1.86 3.33 1.94 4.86 1.71 3.50 3.90 0.84 
160 1.86 3.33 1.94 4.86 1.71 3.50 3.90 0.84 
170 1.86 3.33 1.92 3.78 1.71 3.44 3.52 0.24 
180 1.87 3.89 1.93 4.32 1.71 3.44 3.88 0.44 
190 1.86 3.33 1.91 3.24 1.71 3.44 3.34 0.10 
210 1.88 4.44 1.91 3.24 1.70 2.75 3.48 0.87 
220 1.88 4.44 1.90 2.70 1.70 2.75 3.30 0.99 
230 1.87 3.89 1.90 2.70 1.71 3.44 3.34 0.60 
240 1.86 3.33 1.90 2.70 1.70 2.75 2.93 0.35 
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FIG. 4 shows the impressive reduction in edema swelling 
when compound PC-16 is injected prior to the Zymosan 
injection. FIG. 4 plots data of Table 4 below). 
TABLE 4 
24 
Zymosan Induced In?ammation in Rats 
Treatment with PC16 
(3.6 X 10‘5 mg/g b.w.) 
Treatment with PC16 
(3.6 x 10‘4 mg/g b.w.) 
Time Control % Volume % Oedema % Volume % Ocderna 
(min) (0.1 ml prop. glyc.) Increase Volume change Increase Volume change 
10 9.53 12.2 28.0 1.43 —85.0 
20 28.5 16.3 —42.8 1.61 —94.4 
30 37.7 17.3 —54.1 2.19 —94.2 
40 45.1 18.8 —58.3 2.37 —94.7 
50 48.8 19.1 —6018 2.37 —95.1 
60 57.0 19.5 —65.8 2.92 —94.9 
65 56.3 19.8 —64.8 2.92 —94.8 
70 58.2 20.0 —65.7 3.13 —94.6 
80 56.7 20.5 -63.9 3.52 —93.8 
95 58.6 19.7 —66.4 3.52 —94.0 
100 58.5 18.6 —68.2 3.33 —94.3 
105 58.8 18.4 —68.7 3.49 —94.1 
115 59.6 17.9 —69.9 3.78 —93.7 
120 58.3 17.7 —69.6 3.90 —93.3 
130 56.7 17.7 —68.8 3.35 —94.1 
135 51.7 17.7 —65.8 3.53 —93.2 
145 50.0 17.7 —64.6 3.71 —92.6 
150 48.3 15.6 —67.7 3.90 —91.9 
160 46.5 15.2 —67.4 3.90 —91.6 
175 43.3 14.4 —66.7 3.70 —91.5 
190 41.1 12.6 —69.2 3.34 —91.9 
200 41.1 13.3 —67.6 3.41 —91.7 
205 39.2 13.5 —65.6 3.41 —91.3 
210 37.3 13.6 —63.4 3.48 —9017 
220 35.0 ‘ 13.6 —61.2 3.30 —90.6 
225 32.6 12.4 —61.9 3.32 —898 
240 32.3 12.1 —62.7 2.93 —90.9 
As pointed out above, the compounds of the invention CH CH 
3"’ _ i may be employed as speci?c active site directed inhibitors of 
the enzyme, elastase. For this purpose, the compounds are 
preferably combined with a pharmaceutically acceptable 
carrier for administration by injection or in the oral form. 
Conventional adjuvant and carriers may be employed in 
combination with about 0.001 to 2.0 weight percent of the 
active compound. 
Conventional adjuvants and methods of administration are 
known in the art as set forth in Remington’s Pharmaceutical 
Sciences, 18th ed., Mack Publishing Co., 1992, incorporated 
herein by reference in its entirety. The compounds may be 
administered to animals or humans at a range between 36 
and 360 ug/kg. 
In sum, the present invention provides for a compound of 
the formula 
wherein R and R' together comprise a primary or a second 
ary aliphatic amine. Preferably the compounds is a primary 
aliphatic amine, wherein R selected from the group consist 
ing of CH3CH2—; CH2:CH—CH2—; 
45 
50 
55 
65 
CH3 
and a phenyl group and R' is H. 
Alternatively, the compound of the invention is a second 
ary aliphatic amine, wherein R‘ is selected from the Group 
consisting of CH3CH2CH2CH2-—; 
CH3 
and R is selected from CH3—-CH2 and 
CH3—lCH—-. 
CH3 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention with 
out implying any limitation. It will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention without departing from the spirit or scope of the 
invention. All publications and patents mentioned herein are 
incorporated by reference in their entireties. 
We claim: 
1. A compound of the formula 
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wherein R and R' are selected from the group consisting of 
alkyl, alkenyl and phenyl amines; and wherein said com 
pound is a primary or secondary amine. 
2. A compound according to claim 1 which is a primary 
amine, wherein R selected from the group consisting of 
CH3CH2CH2CH2—; CH2=CH—CH2—; 
CH3 
and a phenyl group and R' is H. 
3. A compound according to claim 1, which is a secondary 
amine, wherein R‘ is selected from the Group consisting of 
CH3CH2CH2CH2-—; 
CH3 
and R is selected from CH3—CH2 and 
CH3—C|IH—. 
CH3 
4. The compound of claim 1, wherein said compound 
includes a primary amine and said compound is selected 
from the group consisting of N-(n~butyl) l-phenyl-lH 
tetrazole-S-thiocarbamate; N-allyl l-phenyl-lH-tetrazole-S 
thiocarbamate; N~isopropyl l-phenyl lH-tetrazole-S-thio 
carbamate; and N-pheny l-phenyl-lH-tetrazole-S 
thiocarbamate. 
5. The compound of claim 1, wherein said compound is 
a secondary amine selected from the group consisting of 
N-Ethyl, N-n-(Butyl) l-phenyl-lH'tetrazole-5-thiocarbam 
ate, and N,N-diisopropyl 1-phenyl~lH-tetrazole-S-thiocar 
bamate. 
6. A method of selectively inhibiting the enzyme elastase 
in an animal or a human in need of such treatment com 
prising administering to said animal or human an enzyme 
elastase inhibiting amount of the compound of claim 1. 
7. A pharmaceutical composition comprising a compound 
of the formula 
0 
ll 
wherein R and R‘ are selected from the group consisting of 
alkyl, alkenyl and phenyl amines, and wherein said com 
pound is a primary or secondary amine; and a pharmaceu 
tically acceptable carrier. 
8. A pharmaceutical composition according to claim 7, 
wherein said compound is a primary amine, wherein R 
10 
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selected from the group consisting of CH3CH2CH2CH2_; 
CH2=CH——CH2——; 
CH3 
and a phenyl group and R‘ is H. 
9. A pharmaceutical composition according to claim 7, 
wherein said compound is a secondary amine, wherein R' is 
selected from the group consisting of CH3CH2CH2CH2—; 
CH3 
and R is selected from CH3—CH2 and 
CH3—|CH—~. 
CH3 
10. The composition of claim 8, wherein said compound 
includes a primary amine and is selected from the group 
consisting of N-(n-butyl) l-phenyl-lH tetrazole-S-thiocar 
bamate; N-allyl l-phenyl-1H-tetrazole-S-thiocarbamate; 
N-isopropyl l-phenyl-lH-tetrazole~5-thiocarbamate; and 
N-phenyl l-phenyl—lH-tetrazole~5-thiocarbamate. 
11. The composition of claim 7 wherein said compound 
includes a secondary amine and is selected from the group 
consisting of N-Ethyl, N-(n_Butyl) l-phenyl-lH-tetrazole 
S-thiocarbamate and N,N-diisopropyl l-phenyl-lH-tetra~ 
zole~5-thiocarbamate. 
12. A method for the synthesis of the primary thiocar 
bamates of claim 10 as human leucocyte elastase (HLE) 
inhibitors, comprising the steps of: 
(a) reacting a primary amine with excess of carbonyl 
chloride in toluene resulting in tile production of the 
corresponding isocyanate; and, 
(b) reacting the isocyanate with excess of l-phenyl-lH 
tetrazole-S -thiol to produce the corresponding primary 
thiocarbamate. 
13. A method for the synthesis of the secondary thiocar 
barnates of claim 11 human leukocyte elastase (HLE) inhibi~ 
tors, comprising the steps of: 
(a) reacting a secondary amine with excess of carbonyl 
chloride in toluene resulting in the production of the 
corresponding carbamoyl chloride; and, 
(b) reacting the carbamoyl chloride with excess of l-phe 
nyl-lH-tetrazole-S-thiol to produce the corresponding 
secondary thiocarbamates. 
14. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with arthritis. 
15. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with emphysema. 
16. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with bronchitis. 
17. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with acute respi 
ratory distress syndrome (ARDS). 
18. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with cystic ?brosis. 
19. The method of claim 6, wherein said human or animal 
has chronic tissue destruction associated with in?ammation. 
